[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515543":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":48,"collaborators":20,"id":52,"slug":20,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":20,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Hubei Cancer Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Neoadjuvant radiotherapy group","EXPERIMENTAL","Radiotherapy followed by skin-sparing mastectomy and immediate implant-based reconstruction in HBCH",[13],"Radiation: Neoadjuvant radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Neoadjuvant radiotherapy","In case of neoadjuvant chemotherapy, RT will start 3-4 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions or 16 x 2.67Gy 5 fractions per week.\n\nA skin-sparing mastectomy and a immediate implant-based breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Xinhong Wu, MD","CONTACT","+8618602726300","34053889@qq.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Ning Zou, MD","+8615007162698","sunnyning116@163.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Xinhong Wu","RECRUITING","Wuhan","Hubei","430079","China",{"type":40,"coordinates":41},"Point",[42,43],114.26667,30.58333,{"lat":43,"lon":42},[46,47],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Xinhong Wu, PhD","vice-president","100515543",false,"NCT05992870","Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction","Inclusion Criteria:\n\nWomen \\>18 years with histopathologically-confirmed breast cancer, who:\n\n* require mastectomy for any reason\n* a known indication for (adjuvant) radiotherapy\n* require implant-based breast reconstruction\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* MDT unable to make recommendation for radiotherapy based on pre-operative histopathological and imaging findings\n* Previous history of breast cancer or another malignancy for which radiotherapy of the breast or axilla\n* Pregnant or lactating\n* inflammatory breast cancer","FEMALE","18 Years","75 Years",{"count":61,"type":62},40,"ESTIMATED","INTERVENTIONAL",[65],"NA","Neoadjuvant radiotherapy(NART) followed by mastectomy and immediate DIEP flap reconstruction is feasible and technically safe. However, reports of NACT followed immediate implant-based breast reconstruction are rare. Some studies have shown that NART followed immediate implant-based breast reconstruction seems feasible and can be safely attempted. It's well known that radiotherapy after implant-based breast reconstruction have negative effects on implant and cosmetic results. So, investigators conducted a polit study to learn about acute post-surgical complications following skin-sparing mastectomy and immediate implant-based breast reconstruction after NART.",[68,69,70],"Breast Cancer","Implant Breast Reconstruction","Neoadjuvant Radiotherapy",[72],"neoadjuvant radiotherapy, implant, breast reconstruction","2025-03-14",{"date":75,"type":76},"2025-03-17","ACTUAL",{"date":78,"type":76},"2023-07-08",{"date":80,"type":62},"2025-10-31",{"name":5,"class":6},1]